Silvano Chiapparoli Logistica SpA   Report issue

For profit Phase 2
Founded: Milan Italy (1979)

Organization Overview

First Clinical Trial
2019
NCT03976518
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Silvano Chiapparoli Logistica SpA

Active Ingredients

Drugs in Phase 2 Trials (1)

atezolizumab (Tecentriq) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1